Maravai LifeSciences Holdings, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Bernd Brust
- Full Time Employees
- 435
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10770 Wateridge Circle San Diego CA United States of America 92121
- IPO Date
- Nov 20, 2020
- CIK
- 0001823239
- Website
- maravai.com
- Similar Companies
- Business
- Maravai LifeSciences Holdings, Inc. is a prominent life sciences firm that supplies essential products enabling the advancement of drug treatments, cell and gene therapies, diagnostics, and cutting-edge vaccines, while also supporting research into human health challenges across global markets. The company’s offerings span the critical stages of biopharmaceutical development, encompassing complex nucleic acids for both diagnostic and therapeutic purposes, as well as antibody-based reagents designed to detect impurities during the manufacture of biopharmaceutical compounds, and solutions for identifying protein expression in diverse tissue samples. The organization operates through two primary divisions: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and distributes specialized nucleic acid products and associated services, catering to research, therapeutic, and vaccine development programs, particularly in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This segment includes key innovations like messenger RNA, oligonucleotides, plasmid DNA, and the proprietary CleanCap® mRNA capping technology, along with reagents for chemical synthesis, modification, labeling, and purification of DNA and RNA. Recent initiatives include expanding GMP consumables for mRNA applications and launching new products like the CleanScribe™ RNA Polymerase through its TriLink BioTechnologies and Alphazyme brands. The Biologics Safety Testing segment provides analytical tools for use in the development of biologic manufacturing processes. This includes impurity detection solutions such as HCP ELISA kits and other bioprocess impurity assays, alongside viral clearance prediction kits, ancillary reagents, and custom antibody and assay development services. The company targets a broad client base, including leading global biopharmaceutical companies, emerging life sciences research enterprises, academic institutions, and in vitro diagnostics developers. Founded in 2014 and publicly listed in November 2020, Maravai LifeSciences is headquartered in San Diego, California. The company has recently undergone leadership changes, with a new CEO and CFO appointed in mid-2025, and initiated a restructuring plan aiming for over $50 million in annual cost savings by 2026. While navigating challenging financial results in 2025, the company continues to focus on innovation, evidenced by numerous new product launches and significant expansion in mRNA production capacity.
Dimensional Fund Advisors LP Boosts Holdings in Maravai LifeSciences Holdings, Inc. $MRVI
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Down – Here’s Why
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
Maravai LifeSciences Q2 Earnings Call Highlights
Maravai LifeSciences Q2 Earnings Call Highlights
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates
Maravai LifeSciences Reports Second Quarter 2026 Financial Results
Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026
TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology
TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript
Maravai LifeSciences Q1 Earnings Call Highlights
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates
Maravai LifeSciences Reports First Quarter 2026 Financial Results
All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy